Emosis Revenue and Competitors

Emosis is a MedTech company founded early 2015 by Prof. Aaron Tomer and Dr. Frederic Allemand, to address still largely unmet needs in in vitro diagnostics(IVD) and drug companion testing for hemostasis and thrombosis disorders. These disorders are involved in a broad spectrum of diseases, ranging from stroke, myocardial infarction, and pulmonary embolism to cancer and pregnancy losses. To meet this need, Emosis uniquely applies, in a user-friendly way, the power of flow cytometry technology, which has revolutionized the manner in which hematological malignancies are evaluated, within the emerging paradigm of cell-based hemostasis, to develop a series of assay kits that will enlighten therapeutic decision of the physicians managing those patients. In order to expand its international footprint and enhance its R&D efforts, Emosis has opened in early 2017 a subsidiary in Israel, Emosis Ltd, which will primarily focused on establishing cooperations with Israeli R&D excellence centers. Israel offices are located in Tel-Aviv. The full range of Emosis IVD kits will enable in-hospital laboratories to quickly and routinely test for and assess hemostasis disorders so that patients can immediately receive optimal treatment based on an accurate diagnosis. Our new diagnostic system will significantly improve the care of millions of affected patients worldwide every year. Emosis first diagnostic kit is due for European launch in 2017. It will be used to confirm the diagnosis of Heparin-Induced Thrombocytopenia (HIT). HIT is a rare, but life-threatening, disorder that is frequently suspected in hospital in-patients treated with heparin. For more information, feel free to contact us and to visit our website: www.emosis-diagnostics.com